Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 15/3/2021
SIETES contiene 93212 citas

 
 
 1 a 20 de 117 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Tisdale JE, Chung MK, Campbell KB, Hammadah M, Joglar JA, Rajagopalan B, On behalf of the American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-induced arrhythmias. A scientific statement from the American Heart Association. Circulation 2020;142:16 de septiembre. [Ref.ID 103712]
2. Cita con resumen
Anónimo. Valvulopathies d'origine médicamenteuse. Prescrire 2013;33:668-72. [Ref.ID 96188]
3. Cita con resumen
Montastruc F, Montastruc G, Vigreux P, Bruneval P, Guilbeau-Frugier C, Cron C, Bagheri H, Delisle B, Lapeyre-Mestre M, Pathak A, Montastruc J-L. Valvular heart disease in a patient taking 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). Br J Clin Pharmacol 2012;74:547-8. [Ref.ID 93709]
4. Cita con resumen
Seetohul LN, Maskell PD, De Paoli G, Pounder DJ. Designer drugs. Deaths associated with new designer drug 5-IT. BMJ 2012;345:22. [Ref.ID 93701]
5. Cita con resumen
Blakemore C. Classification of cannabis and ecstasy in the UK. BMJ 2009;338:490-1. [Ref.ID 85381]
6. Cita con resumen
Kmietowicz Z. UK government rejects advice from drugs adviser to downgrade ecstasy. BMJ 2009;338:435. [Ref.ID 85329]
7. Cita con resumen
Morris K. Research on psychedelics moves into the mainstream. Lancet 2008;371:1491-2. [Ref.ID 82795]
8.Tiene citas relacionadas Cita con resumen
Nutt D, King L, Saulsbury W, Blakemore C. Assessing drug-related harm. Authors' reply. Lancet 2007;369:1857. [Ref.ID 80189]
9.Tiene citas relacionadas Cita con resumen
Murphy PN. Assessing drug-related harm. Lancet 2007;369:1856. [Ref.ID 80187]
10. Cita con resumen
Ellison DH, Berl T. The syndrome of inappropriate antidiuresis. N Engl J Med 2007;356:2064-72. [Ref.ID 80043]
11. Cita con resumen
McCarthy M. Prescription drug abuse up sharply in the USA. Lancet 2007;369:1505-6. [Ref.ID 79996]
12.Tiene citas relacionadas Cita con resumen
Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 2007;369:1047-53. [Ref.ID 79592]
13.Tiene citas relacionadas
Hall W. Psychoactive drugs of misuse: rationalising the irrational. Lancet 2007;369:972. [Ref.ID 79586]
14.Tiene citas relacionadas Cita con resumen
Roth BL. Drugs and valvular heart disease. N Engl J Med 2007;356:6-9. [Ref.ID 78770]
15.Enlace a cita original Cita con resumen
Anónimo. Cost of street drugs falls. BMJ 2006;333:1138. [Ref.ID 78637]
16.Enlace a cita original
Lüscher C, Ungless MA. The mechanistic classification of addictive drugs. PLOS Medicine 2006;3:437. [Ref.ID 78605]
17.Tiene citas relacionadas Cita con resumen
Anónimo. Reviving research into psychedelic drugs. Lancet 2006;367:1214. [Ref.ID 76829]
18.Tiene citas relacionadas
Huizink AC, Ferdinand RF, van der Ende J, Verhulst FC. Symptoms of anxiety and depression in childhood and use of MDMA: prospective, population based study. BMJ 2006;332:825-7. [Ref.ID 76698]
19.Tiene citas relacionadas
Poikolainen K. Ecstasy and the antecedents of illicit drug use. BMJ 2006;332:803-4. [Ref.ID 76694]
20.Tiene citas relacionadas Cita con resumen
Ricaurte GA, McCann UD. Recognition and management of complications of new recreational drug use. Lancet 2005;365:2137-45. [Ref.ID 76388]
Seleccionar todas
 
 1 a 20 de 117 siguiente >>